In hepatocellular carcinoma (HCC) and bladder cancer (BLCA), elevated SIGLEC15 expression is correlated with a non-inflammatory TME and confers resistance to immunotherapy.15 Here, SIGLEC15 is linked to urinary bladder cancer.